Recent advances in patients with recurrent glioblastoma show that intrathecal delivery of CAR T cells targeting IL13α2 (NCT002208362) (116), or bivalent CAR T cells targeting two antigens, EGFR and IL13α2, (NCT05168423) (113), and EGFR/EGFRvIII with a T-cell engaging antibody, TEAM, (NCT05660369) (115), leads to compelling results (117) assessed by CAR T cell proliferation, rapid reduction in tumor size, bioactivity and safety signals. The gene discussed is EGFR; the disease is neoplasm.